Guillain-Barré syndrome following BNT162b2 COVID-19 vaccine.

Trimboli, Michele; Zoleo, Pio; Arabia, Gennarina; Gambardella, Antonio

Trimboli, Michele; Zoleo, Pio; Arabia, Gennarina; Gambardella, Antonio.

Trimboli M; Department of Medical and Surgical Sciences, Institute of Neurology, Magna Græcia University, V.le Europa, 88100, Catanzaro, Italy.
Zoleo P; Department of Medical and Surgical Sciences, Institute of Neurology, Magna Græcia University, V.le Europa, 88100, Catanzaro, Italy.
Arabia G; Department of Medical and Surgical Sciences, Institute of Neurology, Magna Græcia University, V.le Europa, 88100, Catanzaro, Italy.
Gambardella A; Department of Medical and Surgical Sciences, Institute of Neurology, Magna Græcia University, V.le Europa, 88100, Catanzaro, Italy. a.gambardella@unicz.it.

Neurol Sci ; 42(11): 4401-4402, 2021 Nov.

Article in English | MEDLINE | ID: covidwho-1469716

Subject(s)

COVID-19; Guillain-Barre Syndrome; BNT162 Vaccine; COVID-19 Vaccines; Guillain-Barre Syndrome/etiology; Humans; SARS-CoV-2

Fulltext

XML

PubMed Links

Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Guillain-Barre Syndrome / COVID-19 Topics: Vaccines Limits: Humans Language: English Journal: Neurol Sci Journal subject: Neurology Year: 2021 Document Type: Article Affiliation country: S10072-021-05523-5

Similar

MEDLINE

LILACS

LIS

Fulltext

XML

PubMed Links

Search on Google